Contains fulltext : 47999schalken.pdf (publisher's version ) (Closed access)An overview is given of serum and urine prostate cancer markers that are currently under investigation and subsequently the P-Mark project is introduced. There are many markers showing promise to overcome the limitations of prostate specific antigen (PSA). Eventually, these markers should be able to increase the specificity in diagnosis, differentiate between harmless and aggressive disease and identify progression towards androgen independence at an early stage. In the P-Mark project, several recently developed, promising markers will be evaluated using clinically well-defined biorepositories. Following successful evaluation, these markers will be...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
Contains fulltext : 81968.pdf (publisher's version ) (Open Access)Serum PSA has sh...
This review concentrates mainly on currently available markers for prostate cancer and cannot cover ...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
Contains fulltext : 58214.pdf (publisher's version ) (Closed access)Early diagnosi...
Item does not contain fulltextSerum PSA testing has been used for over 20 years as an aid in the dia...
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the dis...
Contains fulltext : 177633.pdf (publisher's version ) (Open Access)INTRODUCTION: M...
Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of cancer-rela...
The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the...
Contains fulltext : 173475.pdf (publisher's version ) (Open Access)Radboud Univers...
© 2017 Elsevier B.V. Prostate cancer (CaP) is the most common cancer in men and the second leading c...
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading cause o...
Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify progn...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
Contains fulltext : 81968.pdf (publisher's version ) (Open Access)Serum PSA has sh...
This review concentrates mainly on currently available markers for prostate cancer and cannot cover ...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
An overview is given of serum and urine prostate cancer markers that are currently under investigati...
Contains fulltext : 58214.pdf (publisher's version ) (Closed access)Early diagnosi...
Item does not contain fulltextSerum PSA testing has been used for over 20 years as an aid in the dia...
In order to successfully cure patients with prostate cancer (PCa), it is important to detect the dis...
Contains fulltext : 177633.pdf (publisher's version ) (Open Access)INTRODUCTION: M...
Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of cancer-rela...
The main diagnostic biomarker in current use is prostate-specific antigen (PSA) and it is one of the...
Contains fulltext : 173475.pdf (publisher's version ) (Open Access)Radboud Univers...
© 2017 Elsevier B.V. Prostate cancer (CaP) is the most common cancer in men and the second leading c...
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading cause o...
Prostate cancer (caP) is a major public health problem. Many groups have attempted to identify progn...
The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revol...
Contains fulltext : 81968.pdf (publisher's version ) (Open Access)Serum PSA has sh...
This review concentrates mainly on currently available markers for prostate cancer and cannot cover ...